2023 Revenue Guidance BioLife Solutions is updating 2023 revenue guidance, which is based on expectations for its existing business. Total revenue for 2023 is expected to range from $144

BLFS

BridgeBio Pharma Announces Results Of Five New Analyses Of Clinical Endpoints From Phase 3 ATTRibute-CM Study of Acoramidis In ATTR-CM At ISA

By Benzinga Newsdesk

May 29, 4:03 PM

- Acoramidis treatment resulted in increased serum transthyretin (TTR) levels by Day 28 that were sustained and were correlated with a reduced risk of all-cause mortality (ACM), cardiovascular mortality (CVM), and

BBIO

Verastem Oncology Granted Fast Track Designation For Combination Of Avutometinib And Sotorasib For The Treatment Of KRAS G12C-Mutant Non-Small Cell Lung Cancer

By Benzinga Newsdesk

January 18, 5:00 PM

Ongoing RAMP 203 Trial Assessing a More Complete Vertical Blockade with RAF/MEK and KRAS G12C Inhibition Along RAS Pathway to Improve Outcomes in KRAS G12C-Mutant NSCLCConfirmed Responses Observed in Both KRAS G12C

VSTM

Exane BNP Paribas Downgrades Thomson Reuters to Underperform

Related Posts

5 Analysts Have This to Say About PerkinElmer

BioLife Solutions Sees FY23 Revenue $144M-$158M Vs $186.31M Est.

BridgeBio Pharma Announces Results Of Five New Analyses Of Clinical Endpoints From Phase 3 ATTRibute-CM Study of Acoramidis In ATTR-CM At ISA

Verastem Oncology Granted Fast Track Designation For Combination Of Avutometinib And Sotorasib For The Treatment Of KRAS G12C-Mutant Non-Small Cell Lung Cancer